Atopic Dermatitis - Pipeline Insight, 2024

This “Atopic Dermatitis - Pipeline Insight, 2024” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Atopic Dermatitis: Understanding

Atopic Dermatitis: Overview

Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’ Thus, dermatitis is a skin inflammation characterized by itchiness, redness and a rash caused by genetics, an overactive immune system, infections, allergies, and irritating substances. Half of the patients with moderate-to-severe eczema also have asthma, hay fever (allergic rhinitis), and food allergies. It is the most common chronic skin disease in children.

The pathophysiology of AD is complex and multifactorial, involving elements of barrier dysfunction, alterations in cell-mediated immune responses, IgE mediated hypersensitivity, and environmental factors. Loss of function mutations in filaggrin has been implicated in severe AD due to a potential increase in trans-epidermal water loss, pH alterations, and dehydration. Other genetic changes have also been identified which may alter the skin’s barrier function, resulting in an AD phenotype. The imbalance of Th2 to Th1 cytokines observed in AD can create alterations in the cell-mediated immune responses and promote IgE mediated hypersensitivity, both of which appear to play a role in the development of AD. Eczema can be characterized by spongiosis which allows inflammatory mediators to accumulate. Different dendritic cells subtypes, such as Langerhans cells, inflammatory dendritic epidermal cells, and plasmacytoid dendritic cells, play a major role in developing the condition.

The exact cause of AD is unknown. The basic understanding of AD is that inflammation results from the presence of too many inflammatory cells in the skin. There is also evidence that people with AD have a compromised skin barrier compared to normal skin. Because of the altered skin barrier, people with AD have drier skin that is more prone to water loss and the entry of irritants leading to the development of red, itchy rashes. Thus, AD is caused by a complex interaction of immune dysregulation, epidermal gene mutations, and environmental factors that disrupt the epidermis causing intensely pruritic skin lesions. However, it is not contagious.

The diagnosis is based on signs and symptoms. Other diseases that must be excluded before making a diagnosis include contact dermatitis, psoriasis, and seborrheic dermatitis. It can significantly impact the quality of life, not just that of the patient, but family and friends as well. The itch can make it difficult to concentrate, and poor sleep can make people feel like zombies during the day. Also, Systemic Treatment s and precautions can take a toll on time, energy, and money. The condition usually improves or clears up if the substance causing the problem is identified and avoided. Although there is no cure, available Systemic Treatment s help ease the symptoms (American Academy of Allergy, Asthma & Immunology.

Atopic Dermatitis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atopic Dermatitis pipeline landscape is provided which includes the disease overview and Atopic Dermatitis treatment guidelines. The assessment part of the report embraces, in depth Atopic Dermatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atopic Dermatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis R&D. The therapies under development are focused on novel approaches to treat/improve Atopic Dermatitis.

Atopic Dermatitis Emerging Drugs Chapters

This segment of the Atopic Dermatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atopic Dermatitis Emerging Drugs

Tapinarof: Dermavant Sciences Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) that binds and activates the aryl hydrocarbon receptor in multiple cell types, including cells of the target tissue-human skin. Tapinarof has also shown to moderate proinflammatory cytokine expression in stimulated peripheral blood CD4+ T cells and ex vivo human skin, and impact barrier gene expression in primary human keratinocytes. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Atopicdermatitis.

Etrasimod: Pfizer Etrasimod is an oral, once daily, selective sphingosine-1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. In addition to UC, it is being investigated for a range of other immuno-inflammatory diseases and is in Phase II/III stage of development for the treatment of patients with Atopicdermatitis.

B244: AOBiome AOBiome’s B244 is a patented, proprietary, topical formulation incorporating a single strain of beneficial ammonia-oxidizing bacteria (AOB), Nitrosomonas eutropha D23. B244 is designed to repopulate the skin microbiome with AOBs normally found on the body but frequently stripped away by most soaps. Once deployed on the skin, B244 converts ammonia to nitrite, known to have antibacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with Atopicdermatitis.

Lirentelimab: Allakos Inc.Lirentelimab (AK002) is an afucosylated, humanized IgG1 monoclonal antibody which activates the inhibitory receptor Siglec-8. Additionally, Lirentelimab depletes eosinophils via antibody dependent cellular cytotoxicity (ADCC) in blood. Siglec-8 is a member of the family of cell surface receptors called Sialic acid-binding immunoglobulin-type lectins (Siglecs).

Allakos initiated a Phase II trial evaluating subcutaneous Lirentelimab versus placebo in patients with atopic dermatitis. Results from this trial are expected in the second half of 2023.

QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.QY201 acts on Jak1/Tyk2 dual targets with higher activity and selectivity, which is significantly superior to the similar drugs. QY201 is an innovative drug for the treatment of atopic dermatitis. QY201 was independently developed by E-nitiate with global patents, is undergoing Phase I/II clinical trial for atopic dermatitis.

Atopic Dermatitis: Therapeutic Assessment

This segment of the report provides insights about the different Atopic Dermatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Atopic Dermatitis

There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. phase III include, Dermavant Sciences.

Phases

This report covers around 110+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atopic Dermatitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atopic Dermatitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atopic Dermatitis drugs.

Atopic Dermatitis Report Insights

• Atopic Dermatitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Atopic Dermatitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Atopic Dermatitis drugs?
• How many Atopic Dermatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atopic Dermatitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atopic Dermatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atopic Dermatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Dermavant Sciences
• Pfizer
• AOBiome
• Allakos Inc.
• E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
• Eli Lilly and Company
• Vanda Pharmaceuticals
• Suzhou Connect Biopharmaceuticals
• Arcutis Biotherapeutics
• Reistone Biopharma
• Alphyn Biologics
• Argenx
• Shulov Innovate for Science
• Teres Bio
• Qurient Co
• Sun Pharmaceutical
• Merck Sharp & Dohme LLC
• Hangzhou Yirui Pharmaceutical Technology Co., Ltd
• GI Innovation
• AnaptysBio
• MC2 therapeutics
• Akaal Pharma
• Kiniksa Pharmaceuticals
• Selection
• Intrinsic Medicine
• Genome & Company
• TWi Biotechnology

Key Products

• Tapinarof
• Etrasimod
• B244
• Lirentelimab
• QY201
• Lebrikizumab
• Tradipitant
• Roflumilast
• CBP-201
• SHR0302
• AB-101a
• ARGX-112
• ZEP-3Na
• TER-101
• Q301
• SCD-044
• MK-6194
• YR001
• GI-301
• ANB032
• MC2-11 PAD Cream
• AKP-11
• Vixarelimab
• si-544
• OM001
• GEN-501
• AC-1101

This product will be delivered within 1-3 business days.